Back to Journals » Patient Preference and Adherence » Volume 8

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

Authors Rajpal R, Ross B, Rajpal S, Hoang K

Received 13 February 2014

Accepted for publication 11 March 2014

Published 25 June 2014 Volume 2014:8 Pages 925—931


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Rajesh K Rajpal, Bryan Ross, Sachin D Rajpal, Khoa Hoang

See Clearly Vision Group, McLean, VA, USA

Abstract: Ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used by clinicians to manage ocular inflammation and pain following cataract surgery. Over the past decade, the US Food and Drug Administration has approved multiple topical NSAIDs for these purposes, including several reformulated products. One of these medications, bromfenac ophthalmic solution, has a long and extensive history, with proven efficacy and safety in patients following cataract surgery. The evolution of bromfenac ophthalmic solution over the years has involved either lowering the concentration of the active ingredient or extending the dosing interval to improve patient adherence/compliance. This review will focus on the history and progression of bromfenac ophthalmic solution and report the available patient preference and adherence data regarding this ocular NSAID throughout its evolution.

Keywords: cataract surgery, nonsteroidal anti-inflammatory drugs, COX inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]